| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Respiratory Syncytial Virus Infections | 99 | 2025 | 377 | 15.320 |
Why?
|
| Respiratory Syncytial Virus, Human | 62 | 2025 | 233 | 13.440 |
Why?
|
| Bronchiolitis | 53 | 2022 | 123 | 8.040 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 24 | 2025 | 71 | 5.740 |
Why?
|
| Influenza, Human | 45 | 2024 | 700 | 4.560 |
Why?
|
| Antibodies, Viral | 54 | 2025 | 1205 | 4.220 |
Why?
|
| Respiratory Syncytial Viruses | 35 | 2025 | 153 | 4.210 |
Why?
|
| Respiratory Tract Infections | 27 | 2025 | 296 | 4.160 |
Why?
|
| Viral Fusion Proteins | 18 | 2023 | 76 | 3.050 |
Why?
|
| Influenza Vaccines | 30 | 2023 | 498 | 2.960 |
Why?
|
| Picornaviridae Infections | 18 | 2025 | 52 | 2.960 |
Why?
|
| Antiviral Agents | 23 | 2025 | 824 | 2.610 |
Why?
|
| Antibodies, Neutralizing | 23 | 2023 | 498 | 2.440 |
Why?
|
| Viral Load | 17 | 2025 | 411 | 2.360 |
Why?
|
| Rhinovirus | 21 | 2025 | 63 | 2.330 |
Why?
|
| Bronchiolitis, Viral | 14 | 2021 | 30 | 2.210 |
Why?
|
| Infant | 139 | 2025 | 13246 | 2.150 |
Why?
|
| Nasopharynx | 22 | 2022 | 87 | 2.130 |
Why?
|
| Viruses | 9 | 2024 | 128 | 2.080 |
Why?
|
| Hospitalization | 41 | 2024 | 1921 | 1.990 |
Why?
|
| Virus Diseases | 10 | 2022 | 291 | 1.890 |
Why?
|
| Enterovirus | 3 | 2024 | 51 | 1.510 |
Why?
|
| Viral Vaccines | 11 | 2015 | 345 | 1.380 |
Why?
|
| Humans | 238 | 2025 | 133811 | 1.350 |
Why?
|
| Enterovirus Infections | 2 | 2024 | 49 | 1.350 |
Why?
|
| Immunity, Humoral | 2 | 2021 | 75 | 1.350 |
Why?
|
| Metapneumovirus | 8 | 2022 | 52 | 1.310 |
Why?
|
| Respiratory Sounds | 13 | 2021 | 71 | 1.270 |
Why?
|
| Prospective Studies | 56 | 2025 | 6602 | 1.160 |
Why?
|
| Transplant Recipients | 3 | 2021 | 227 | 1.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2021 | 1191 | 1.090 |
Why?
|
| Child, Preschool | 80 | 2025 | 14878 | 1.070 |
Why?
|
| Dibenzothiepins | 3 | 2023 | 3 | 1.060 |
Why?
|
| Female | 140 | 2025 | 71840 | 1.050 |
Why?
|
| Organoids | 3 | 2025 | 299 | 0.980 |
Why?
|
| Immunoglobulin G | 10 | 2021 | 791 | 0.970 |
Why?
|
| Bodily Secretions | 2 | 2016 | 7 | 0.960 |
Why?
|
| Male | 127 | 2025 | 65939 | 0.940 |
Why?
|
| Neutralization Tests | 14 | 2016 | 238 | 0.930 |
Why?
|
| Palivizumab | 6 | 2021 | 48 | 0.930 |
Why?
|
| Viral Tropism | 1 | 2025 | 53 | 0.920 |
Why?
|
| Nanoparticles | 8 | 2025 | 289 | 0.910 |
Why?
|
| Vaccines, Attenuated | 15 | 2019 | 176 | 0.910 |
Why?
|
| Infant, Newborn | 45 | 2025 | 8632 | 0.910 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 9 | 2019 | 189 | 0.900 |
Why?
|
| Nose | 1 | 2025 | 105 | 0.900 |
Why?
|
| Orthomyxoviridae | 8 | 2023 | 52 | 0.900 |
Why?
|
| Triazines | 3 | 2023 | 33 | 0.890 |
Why?
|
| Microbiota | 11 | 2022 | 443 | 0.890 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 6 | 2023 | 123 | 0.890 |
Why?
|
| RNA, Viral | 10 | 2024 | 562 | 0.880 |
Why?
|
| Immunoglobulin A | 4 | 2021 | 215 | 0.870 |
Why?
|
| L-Lactate Dehydrogenase | 3 | 2014 | 67 | 0.860 |
Why?
|
| Adult | 51 | 2025 | 31823 | 0.830 |
Why?
|
| Pyridones | 3 | 2023 | 130 | 0.830 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2022 | 356 | 0.830 |
Why?
|
| Morpholines | 2 | 2020 | 64 | 0.830 |
Why?
|
| Cystic Fibrosis | 7 | 2007 | 266 | 0.810 |
Why?
|
| Adenoviridae | 13 | 2022 | 606 | 0.790 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2016 | 805 | 0.760 |
Why?
|
| Immunity, Mucosal | 2 | 2025 | 94 | 0.750 |
Why?
|
| Single-Cell Analysis | 1 | 2025 | 357 | 0.750 |
Why?
|
| Child | 65 | 2025 | 25882 | 0.740 |
Why?
|
| Seasons | 10 | 2024 | 330 | 0.740 |
Why?
|
| Cytokines | 8 | 2024 | 1381 | 0.730 |
Why?
|
| Asthma | 11 | 2021 | 811 | 0.720 |
Why?
|
| Viral Structural Proteins | 1 | 2021 | 47 | 0.710 |
Why?
|
| Virus Replication | 14 | 2025 | 634 | 0.690 |
Why?
|
| Genome, Viral | 5 | 2025 | 184 | 0.690 |
Why?
|
| Antigens, Viral | 10 | 2024 | 438 | 0.680 |
Why?
|
| Disease Outbreaks | 7 | 2023 | 330 | 0.670 |
Why?
|
| Vaccination | 17 | 2023 | 1019 | 0.630 |
Why?
|
| Nasal Mucosa | 5 | 2024 | 68 | 0.620 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 2 | 2024 | 62 | 0.610 |
Why?
|
| Genotype | 12 | 2025 | 2819 | 0.610 |
Why?
|
| Community-Acquired Infections | 3 | 2013 | 247 | 0.610 |
Why?
|
| Bordetella pertussis | 2 | 2016 | 16 | 0.600 |
Why?
|
| Bacterial Infections | 2 | 2019 | 329 | 0.600 |
Why?
|
| Immunity, Maternally-Acquired | 2 | 2014 | 35 | 0.580 |
Why?
|
| Influenza B virus | 7 | 2015 | 100 | 0.580 |
Why?
|
| Adolescent | 43 | 2025 | 20610 | 0.570 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 240 | 0.560 |
Why?
|
| Cohort Studies | 24 | 2024 | 5219 | 0.560 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2019 | 491 | 0.560 |
Why?
|
| Genes, Viral | 2 | 2017 | 186 | 0.550 |
Why?
|
| Real-Time Polymerase Chain Reaction | 9 | 2021 | 545 | 0.550 |
Why?
|
| Adenoviridae Infections | 4 | 2008 | 71 | 0.540 |
Why?
|
| Virus Shedding | 5 | 2021 | 82 | 0.540 |
Why?
|
| Paramyxoviridae Infections | 6 | 2022 | 49 | 0.530 |
Why?
|
| Molecular Diagnostic Techniques | 5 | 2022 | 179 | 0.530 |
Why?
|
| Texas | 14 | 2021 | 3720 | 0.530 |
Why?
|
| Adenovirus Infections, Human | 5 | 2003 | 57 | 0.520 |
Why?
|
| Length of Stay | 11 | 2017 | 1392 | 0.520 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 395 | 0.510 |
Why?
|
| Sigmodontinae | 13 | 2025 | 44 | 0.510 |
Why?
|
| Adjuvants, Immunologic | 9 | 2025 | 391 | 0.510 |
Why?
|
| Viral Proteins | 6 | 2016 | 360 | 0.500 |
Why?
|
| Severity of Illness Index | 23 | 2022 | 3107 | 0.500 |
Why?
|
| Immunization Programs | 4 | 2008 | 65 | 0.490 |
Why?
|
| Adenoviruses, Human | 4 | 2003 | 99 | 0.480 |
Why?
|
| Influenza A virus | 11 | 2015 | 152 | 0.470 |
Why?
|
| Young Adult | 21 | 2021 | 9926 | 0.470 |
Why?
|
| Nasal Lavage Fluid | 3 | 2016 | 14 | 0.470 |
Why?
|
| Lung | 13 | 2025 | 1573 | 0.460 |
Why?
|
| Common Cold | 4 | 2019 | 24 | 0.460 |
Why?
|
| Vaccines, Synthetic | 8 | 2020 | 322 | 0.460 |
Why?
|
| Whooping Cough | 1 | 2015 | 61 | 0.450 |
Why?
|
| Infant, Premature, Diseases | 3 | 2010 | 254 | 0.430 |
Why?
|
| Administration, Intranasal | 13 | 2025 | 138 | 0.430 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2014 | 87 | 0.420 |
Why?
|
| Antibody Formation | 6 | 2021 | 273 | 0.420 |
Why?
|
| Caspases | 1 | 2014 | 166 | 0.420 |
Why?
|
| Immunity, Innate | 4 | 2025 | 415 | 0.410 |
Why?
|
| Continuous Positive Airway Pressure | 2 | 2015 | 61 | 0.400 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2025 | 555 | 0.400 |
Why?
|
| Coinfection | 5 | 2024 | 182 | 0.400 |
Why?
|
| Genetic Variation | 7 | 2025 | 1630 | 0.390 |
Why?
|
| Drug Resistance, Viral | 6 | 2025 | 50 | 0.390 |
Why?
|
| HN Protein | 3 | 1998 | 18 | 0.390 |
Why?
|
| Coronavirus | 3 | 2022 | 27 | 0.380 |
Why?
|
| Infant, Premature | 3 | 2020 | 857 | 0.380 |
Why?
|
| Vaccines, Inactivated | 6 | 2019 | 148 | 0.380 |
Why?
|
| Metabolome | 5 | 2021 | 322 | 0.380 |
Why?
|
| Middle Aged | 26 | 2025 | 29287 | 0.370 |
Why?
|
| Antimicrobial Cationic Peptides | 3 | 2017 | 39 | 0.360 |
Why?
|
| Oseltamivir | 2 | 2022 | 19 | 0.360 |
Why?
|
| Pregnancy | 14 | 2022 | 7599 | 0.360 |
Why?
|
| United States | 24 | 2025 | 11760 | 0.350 |
Why?
|
| Phenotype | 1 | 2021 | 4593 | 0.350 |
Why?
|
| Acute Disease | 9 | 2025 | 1185 | 0.340 |
Why?
|
| Immunity, Herd | 3 | 2010 | 13 | 0.340 |
Why?
|
| Spike Glycoprotein, Coronavirus | 3 | 2021 | 204 | 0.330 |
Why?
|
| Age Factors | 10 | 2025 | 2987 | 0.320 |
Why?
|
| Lung Diseases | 5 | 2016 | 407 | 0.320 |
Why?
|
| Nasal Cavity | 4 | 2018 | 52 | 0.320 |
Why?
|
| Intubation, Intratracheal | 2 | 2012 | 291 | 0.310 |
Why?
|
| Respiratory Tract Diseases | 5 | 2022 | 81 | 0.310 |
Why?
|
| Cell Line | 8 | 2023 | 2861 | 0.310 |
Why?
|
| Eczema | 2 | 2021 | 30 | 0.310 |
Why?
|
| Cost of Illness | 2 | 2025 | 277 | 0.310 |
Why?
|
| Double-Blind Method | 10 | 2020 | 1663 | 0.300 |
Why?
|
| Cross Infection | 4 | 2021 | 344 | 0.300 |
Why?
|
| Social Change | 1 | 2008 | 15 | 0.300 |
Why?
|
| Single-Domain Antibodies | 2 | 2020 | 9 | 0.290 |
Why?
|
| Respirovirus Infections | 6 | 2017 | 20 | 0.290 |
Why?
|
| Vaccines, Virus-Like Particle | 2 | 2019 | 34 | 0.290 |
Why?
|
| Aged | 20 | 2021 | 21714 | 0.290 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2019 | 404 | 0.290 |
Why?
|
| Finland | 8 | 2021 | 46 | 0.280 |
Why?
|
| Sequence Analysis, DNA | 5 | 2024 | 1834 | 0.280 |
Why?
|
| Ribavirin | 4 | 2003 | 89 | 0.280 |
Why?
|
| Pandemics | 6 | 2023 | 1193 | 0.280 |
Why?
|
| Animals | 37 | 2025 | 36222 | 0.280 |
Why?
|
| Intensive Care Units | 5 | 2020 | 541 | 0.270 |
Why?
|
| Longitudinal Studies | 6 | 2025 | 1516 | 0.270 |
Why?
|
| Infant, Low Birth Weight | 3 | 2020 | 176 | 0.270 |
Why?
|
| Moraxella | 4 | 2019 | 15 | 0.270 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 3739 | 0.260 |
Why?
|
| Haemophilus | 4 | 2019 | 14 | 0.260 |
Why?
|
| Genetic Vectors | 8 | 2014 | 966 | 0.260 |
Why?
|
| Liposomes | 2 | 2025 | 207 | 0.260 |
Why?
|
| Bronchodilator Agents | 4 | 2017 | 153 | 0.250 |
Why?
|
| Administration, Oral | 4 | 2025 | 719 | 0.250 |
Why?
|
| Host-Pathogen Interactions | 3 | 2025 | 265 | 0.250 |
Why?
|
| Gene Expression Profiling | 4 | 2025 | 1917 | 0.240 |
Why?
|
| Viral Envelope Proteins | 4 | 2020 | 155 | 0.240 |
Why?
|
| Nucleosides | 1 | 2025 | 19 | 0.240 |
Why?
|
| Protein Conformation | 2 | 2018 | 873 | 0.240 |
Why?
|
| Respiratory System | 3 | 2021 | 98 | 0.240 |
Why?
|
| Drug Discovery | 2 | 2018 | 180 | 0.230 |
Why?
|
| Streptococcus | 3 | 2019 | 63 | 0.230 |
Why?
|
| Fever | 3 | 2024 | 312 | 0.230 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2004 | 28 | 0.220 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2003 | 151 | 0.220 |
Why?
|
| Phylogeny | 6 | 2025 | 781 | 0.220 |
Why?
|
| Child Welfare | 1 | 2004 | 67 | 0.220 |
Why?
|
| Mice, Inbred BALB C | 9 | 2025 | 1083 | 0.220 |
Why?
|
| Polymerase Chain Reaction | 5 | 2016 | 1616 | 0.220 |
Why?
|
| Critical Care | 5 | 2017 | 698 | 0.220 |
Why?
|
| Pregnancy Complications | 2 | 2022 | 553 | 0.210 |
Why?
|
| Immunocompromised Host | 5 | 2017 | 305 | 0.210 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2020 | 842 | 0.210 |
Why?
|
| Placebos | 4 | 2019 | 239 | 0.210 |
Why?
|
| Acetamides | 1 | 2024 | 51 | 0.210 |
Why?
|
| Pharynx | 3 | 2016 | 69 | 0.210 |
Why?
|
| Staphylococcus | 3 | 2018 | 69 | 0.210 |
Why?
|
| Poliovirus | 1 | 2023 | 48 | 0.210 |
Why?
|
| Thiepins | 1 | 2023 | 1 | 0.200 |
Why?
|
| Sulfonamides | 2 | 2015 | 289 | 0.200 |
Why?
|
| Disease Models, Animal | 7 | 2025 | 4760 | 0.200 |
Why?
|
| Incidence | 9 | 2021 | 3416 | 0.200 |
Why?
|
| Epidemiological Monitoring | 2 | 2024 | 63 | 0.200 |
Why?
|
| Respiratory Mucosa | 2 | 2020 | 98 | 0.200 |
Why?
|
| Pyrazoles | 2 | 2015 | 334 | 0.200 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 7195 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 6 | 2018 | 1049 | 0.190 |
Why?
|
| Bacteria | 2 | 2019 | 537 | 0.190 |
Why?
|
| Amino Acid Sequence | 3 | 2017 | 2785 | 0.190 |
Why?
|
| Caliciviridae Infections | 1 | 2025 | 359 | 0.180 |
Why?
|
| Biomarkers | 5 | 2019 | 3422 | 0.180 |
Why?
|
| Interleukin-4 | 2 | 2001 | 148 | 0.180 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2015 | 243 | 0.180 |
Why?
|
| Formaldehyde | 2 | 1993 | 38 | 0.180 |
Why?
|
| Drug Administration Schedule | 4 | 2020 | 748 | 0.180 |
Why?
|
| Chemokine CCL5 | 2 | 2018 | 52 | 0.180 |
Why?
|
| Norovirus | 1 | 2025 | 348 | 0.180 |
Why?
|
| Interferon-gamma | 2 | 2017 | 536 | 0.180 |
Why?
|
| Transcriptome | 2 | 2025 | 1135 | 0.180 |
Why?
|
| Viremia | 3 | 2014 | 134 | 0.170 |
Why?
|
| Kava | 1 | 2020 | 8 | 0.170 |
Why?
|
| Lipids | 1 | 2004 | 565 | 0.170 |
Why?
|
| Drug Compounding | 1 | 2020 | 43 | 0.170 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2018 | 158 | 0.170 |
Why?
|
| Recombinant Proteins | 3 | 2021 | 1433 | 0.170 |
Why?
|
| Endonucleases | 1 | 2020 | 59 | 0.170 |
Why?
|
| Rats | 9 | 2018 | 3851 | 0.170 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2020 | 182 | 0.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2008 | 453 | 0.170 |
Why?
|
| Smoking | 3 | 2015 | 1134 | 0.160 |
Why?
|
| Antigenic Variation | 2 | 2017 | 42 | 0.160 |
Why?
|
| Recurrence | 6 | 2021 | 1470 | 0.160 |
Why?
|
| Population Surveillance | 2 | 2017 | 418 | 0.160 |
Why?
|
| Immunity, Cellular | 2 | 2017 | 203 | 0.160 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 74 | 0.160 |
Why?
|
| Coxsackievirus Infections | 1 | 2019 | 10 | 0.160 |
Why?
|
| T-Lymphocytes, Cytotoxic | 5 | 2004 | 520 | 0.160 |
Why?
|
| Chronic Disease | 3 | 2016 | 1234 | 0.160 |
Why?
|
| Vero Cells | 4 | 2020 | 113 | 0.160 |
Why?
|
| Chile | 3 | 2017 | 27 | 0.150 |
Why?
|
| T-Lymphocytes | 4 | 2021 | 1770 | 0.150 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2017 | 107 | 0.150 |
Why?
|
| Cities | 3 | 2024 | 51 | 0.150 |
Why?
|
| Peptides | 2 | 2021 | 863 | 0.150 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2019 | 54 | 0.150 |
Why?
|
| HEK293 Cells | 1 | 2021 | 824 | 0.150 |
Why?
|
| Treatment Outcome | 17 | 2020 | 13114 | 0.150 |
Why?
|
| Blood Proteins | 1 | 2019 | 138 | 0.150 |
Why?
|
| Kinetics | 1 | 2021 | 1323 | 0.150 |
Why?
|
| Immunoglobulin E | 2 | 2019 | 171 | 0.150 |
Why?
|
| Risk Assessment | 5 | 2020 | 3746 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2013 | 1329 | 0.150 |
Why?
|
| Drug Carriers | 2 | 2014 | 119 | 0.150 |
Why?
|
| Respiration | 1 | 1999 | 124 | 0.150 |
Why?
|
| Japan | 3 | 2023 | 153 | 0.150 |
Why?
|
| Laboratories | 1 | 2019 | 89 | 0.150 |
Why?
|
| Global Health | 2 | 2020 | 622 | 0.140 |
Why?
|
| Allografts | 1 | 2019 | 199 | 0.140 |
Why?
|
| Virus Internalization | 2 | 2015 | 61 | 0.140 |
Why?
|
| Hand, Foot and Mouth Disease | 1 | 2017 | 3 | 0.140 |
Why?
|
| Risk Factors | 11 | 2021 | 11166 | 0.140 |
Why?
|
| Cell Proliferation | 1 | 2025 | 2559 | 0.140 |
Why?
|
| Vietnam | 1 | 2017 | 63 | 0.140 |
Why?
|
| Retrospective Studies | 9 | 2020 | 17577 | 0.140 |
Why?
|
| Aluminum Compounds | 2 | 2018 | 17 | 0.140 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 2017 | 12 | 0.140 |
Why?
|
| Respiration, Artificial | 3 | 2015 | 500 | 0.140 |
Why?
|
| Maternal Exposure | 1 | 2019 | 156 | 0.140 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 154 | 0.140 |
Why?
|
| Seroepidemiologic Studies | 2 | 2021 | 144 | 0.140 |
Why?
|
| Logistic Models | 4 | 2015 | 1902 | 0.130 |
Why?
|
| Injections, Intramuscular | 3 | 2020 | 198 | 0.130 |
Why?
|
| Albuterol | 1 | 2017 | 52 | 0.130 |
Why?
|
| Phosphates | 2 | 2018 | 119 | 0.130 |
Why?
|
| Risk | 3 | 2019 | 830 | 0.130 |
Why?
|
| Immunization Schedule | 4 | 2020 | 107 | 0.130 |
Why?
|
| Macrolides | 1 | 2016 | 31 | 0.130 |
Why?
|
| Multivariate Analysis | 4 | 2015 | 1485 | 0.130 |
Why?
|
| HIV Infections | 2 | 2019 | 2075 | 0.130 |
Why?
|
| Health Care Costs | 1 | 2020 | 409 | 0.130 |
Why?
|
| Machine Learning | 1 | 2020 | 344 | 0.130 |
Why?
|
| Time Factors | 6 | 2020 | 6554 | 0.130 |
Why?
|
| Azithromycin | 1 | 2016 | 46 | 0.130 |
Why?
|
| Interferons | 2 | 2017 | 144 | 0.130 |
Why?
|
| Epinephrine | 1 | 2017 | 176 | 0.130 |
Why?
|
| Administration, Inhalation | 7 | 2020 | 186 | 0.120 |
Why?
|
| Cystitis | 1 | 1996 | 51 | 0.120 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 417 | 0.120 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 1488 | 0.120 |
Why?
|
| Food Hypersensitivity | 1 | 2019 | 167 | 0.120 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2015 | 13 | 0.120 |
Why?
|
| NF-kappa B | 1 | 2018 | 478 | 0.120 |
Why?
|
| Feces | 2 | 2016 | 783 | 0.120 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2017 | 899 | 0.120 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 2014 | 12 | 0.120 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 637 | 0.110 |
Why?
|
| Prevalence | 4 | 2015 | 2639 | 0.110 |
Why?
|
| Molecular Typing | 3 | 2021 | 34 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 385 | 0.110 |
Why?
|
| Nonprescription Drugs | 1 | 2015 | 54 | 0.110 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2015 | 94 | 0.110 |
Why?
|
| Outpatients | 2 | 2021 | 275 | 0.110 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2016 | 123 | 0.110 |
Why?
|
| Hyponatremia | 1 | 2015 | 75 | 0.110 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2015 | 129 | 0.110 |
Why?
|
| Papio | 4 | 2021 | 60 | 0.110 |
Why?
|
| Cough | 1 | 2015 | 96 | 0.110 |
Why?
|
| Transcription, Genetic | 1 | 2020 | 1757 | 0.110 |
Why?
|
| Prognosis | 5 | 2015 | 5071 | 0.110 |
Why?
|
| Nasopharyngitis | 1 | 2013 | 5 | 0.110 |
Why?
|
| Proteobacteria | 1 | 2013 | 18 | 0.110 |
Why?
|
| Patient Discharge | 2 | 2015 | 521 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 2575 | 0.100 |
Why?
|
| Apnea | 1 | 2013 | 31 | 0.100 |
Why?
|
| Mass Vaccination | 1 | 2013 | 14 | 0.100 |
Why?
|
| Case-Control Studies | 5 | 2023 | 3644 | 0.100 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 5455 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 2303 | 0.100 |
Why?
|
| Vaccines, Virosome | 1 | 2012 | 1 | 0.100 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2023 | 130 | 0.100 |
Why?
|
| Sf9 Cells | 1 | 2012 | 10 | 0.100 |
Why?
|
| Polysaccharides | 1 | 2014 | 152 | 0.100 |
Why?
|
| Sequence Alignment | 1 | 2014 | 631 | 0.100 |
Why?
|
| Technology, Pharmaceutical | 1 | 2012 | 21 | 0.100 |
Why?
|
| Vaccines | 1 | 2017 | 380 | 0.100 |
Why?
|
| Biotechnology | 1 | 2012 | 61 | 0.100 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 81 | 0.100 |
Why?
|
| Immunization | 5 | 1997 | 315 | 0.100 |
Why?
|
| Odds Ratio | 4 | 2016 | 1323 | 0.100 |
Why?
|
| Immunoglobulins | 2 | 1990 | 169 | 0.100 |
Why?
|
| Mutation | 2 | 2024 | 6350 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 343 | 0.090 |
Why?
|
| Single-Blind Method | 1 | 2012 | 250 | 0.090 |
Why?
|
| Cathelicidins | 3 | 2017 | 13 | 0.090 |
Why?
|
| Picornaviridae | 1 | 2011 | 21 | 0.090 |
Why?
|
| Pregnancy Trimester, Third | 3 | 2020 | 124 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 3 | 2014 | 353 | 0.090 |
Why?
|
| Disease Susceptibility | 3 | 2024 | 320 | 0.090 |
Why?
|
| Sensitivity and Specificity | 4 | 2021 | 2153 | 0.090 |
Why?
|
| Vaccines, Subunit | 2 | 2021 | 70 | 0.090 |
Why?
|
| Cattle | 2 | 2024 | 588 | 0.090 |
Why?
|
| Orthomyxoviridae Infections | 2 | 2024 | 63 | 0.090 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 3966 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 4006 | 0.090 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 151 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2018 | 946 | 0.080 |
Why?
|
| Cross Reactions | 3 | 2004 | 193 | 0.080 |
Why?
|
| Cluster Analysis | 3 | 2017 | 437 | 0.080 |
Why?
|
| Serotyping | 2 | 2008 | 178 | 0.080 |
Why?
|
| Otitis Media | 2 | 2009 | 90 | 0.080 |
Why?
|
| School Health Services | 1 | 2010 | 102 | 0.080 |
Why?
|
| Immunization, Passive | 1 | 1990 | 129 | 0.080 |
Why?
|
| Klebsiella | 1 | 1989 | 10 | 0.080 |
Why?
|
| Age Distribution | 1 | 2010 | 434 | 0.080 |
Why?
|
| Antibody Affinity | 2 | 2020 | 41 | 0.080 |
Why?
|
| Arvicolinae | 1 | 1989 | 4 | 0.080 |
Why?
|
| Mice | 12 | 2025 | 18936 | 0.080 |
Why?
|
| Malabsorption Syndromes | 1 | 1989 | 37 | 0.080 |
Why?
|
| Premature Birth | 1 | 2013 | 419 | 0.080 |
Why?
|
| Culture Techniques | 2 | 2004 | 79 | 0.070 |
Why?
|
| Short Bowel Syndrome | 1 | 1989 | 66 | 0.070 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 3047 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 772 | 0.070 |
Why?
|
| DNA Primers | 3 | 2019 | 671 | 0.070 |
Why?
|
| Macaca fascicularis | 2 | 2020 | 88 | 0.070 |
Why?
|
| Schools, Nursery | 1 | 2007 | 3 | 0.070 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2020 | 114 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2020 | 824 | 0.070 |
Why?
|
| Catheterization, Central Venous | 1 | 1989 | 139 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2015 | 835 | 0.070 |
Why?
|
| Genetic Therapy | 3 | 2002 | 737 | 0.070 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2005 | 336 | 0.070 |
Why?
|
| Lipid Metabolism | 2 | 2020 | 387 | 0.060 |
Why?
|
| Chemokines | 1 | 2007 | 132 | 0.060 |
Why?
|
| Epithelial Cells | 2 | 2024 | 932 | 0.060 |
Why?
|
| Morbidity | 1 | 2007 | 255 | 0.060 |
Why?
|
| Gastroenteritis | 2 | 2025 | 366 | 0.060 |
Why?
|
| Indazoles | 2 | 2015 | 31 | 0.060 |
Why?
|
| Oligonucleotide Probes | 1 | 2025 | 98 | 0.060 |
Why?
|
| Aerosols | 3 | 2002 | 65 | 0.060 |
Why?
|
| Metabolomics | 2 | 2020 | 471 | 0.060 |
Why?
|
| Health Services | 1 | 2005 | 73 | 0.060 |
Why?
|
| Michigan | 1 | 2005 | 52 | 0.060 |
Why?
|
| Liver | 4 | 2002 | 1860 | 0.060 |
Why?
|
| Pseudomonas Infections | 1 | 1986 | 122 | 0.060 |
Why?
|
| Livestock | 1 | 2024 | 12 | 0.060 |
Why?
|
| Farmers | 1 | 2024 | 13 | 0.060 |
Why?
|
| Epitopes | 2 | 2018 | 444 | 0.060 |
Why?
|
| Office Visits | 1 | 2005 | 78 | 0.060 |
Why?
|
| Consumer Product Safety | 1 | 2004 | 32 | 0.060 |
Why?
|
| Sepsis | 1 | 1989 | 522 | 0.060 |
Why?
|
| Influenza in Birds | 1 | 2024 | 30 | 0.060 |
Why?
|
| Adenosine | 1 | 2025 | 140 | 0.060 |
Why?
|
| Birds | 1 | 2024 | 87 | 0.050 |
Why?
|
| Epoxy Compounds | 1 | 2024 | 20 | 0.050 |
Why?
|
| Mutation Rate | 1 | 2024 | 72 | 0.050 |
Why?
|
| DNA, Bacterial | 2 | 2018 | 491 | 0.050 |
Why?
|
| Rotavirus Infections | 1 | 2007 | 357 | 0.050 |
Why?
|
| Gene Expression | 2 | 2021 | 1611 | 0.050 |
Why?
|
| Restriction Mapping | 1 | 2003 | 192 | 0.050 |
Why?
|
| Rotavirus | 1 | 2007 | 502 | 0.050 |
Why?
|
| Registries | 1 | 2010 | 1586 | 0.050 |
Why?
|
| Escherichia coli | 1 | 1989 | 1031 | 0.050 |
Why?
|
| Capsid Proteins | 1 | 2004 | 195 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 3506 | 0.050 |
Why?
|
| Oxazines | 1 | 2023 | 26 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 131 | 0.050 |
Why?
|
| Statistics as Topic | 2 | 2014 | 260 | 0.050 |
Why?
|
| Apoptosis | 1 | 2010 | 1933 | 0.050 |
Why?
|
| Heparin | 1 | 2004 | 230 | 0.050 |
Why?
|
| Crystallography, X-Ray | 1 | 2024 | 393 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 3799 | 0.050 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2022 | 33 | 0.050 |
Why?
|
| Disease Progression | 2 | 2019 | 2255 | 0.050 |
Why?
|
| A549 Cells | 1 | 2022 | 50 | 0.050 |
Why?
|
| Genetic Engineering | 1 | 2003 | 165 | 0.050 |
Why?
|
| Sequence Analysis | 1 | 2021 | 54 | 0.050 |
Why?
|
| Vaccines, Combined | 2 | 1995 | 39 | 0.050 |
Why?
|
| Neuraminidase | 1 | 2022 | 39 | 0.050 |
Why?
|
| Turbinates | 1 | 2021 | 12 | 0.050 |
Why?
|
| Peripartum Period | 1 | 2022 | 29 | 0.050 |
Why?
|
| Blotting, Western | 3 | 2003 | 1137 | 0.050 |
Why?
|
| Immune Evasion | 1 | 2021 | 39 | 0.050 |
Why?
|
| Immune System | 1 | 2002 | 98 | 0.050 |
Why?
|
| Vomiting | 1 | 2002 | 110 | 0.040 |
Why?
|
| Pyridines | 1 | 2023 | 250 | 0.040 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2001 | 19 | 0.040 |
Why?
|
| DNA, Viral | 2 | 2013 | 497 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 424 | 0.040 |
Why?
|
| Species Specificity | 1 | 2022 | 563 | 0.040 |
Why?
|
| Gene Transfer Techniques | 2 | 1999 | 362 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2021 | 220 | 0.040 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 1973 | 0.040 |
Why?
|
| Immune Sera | 1 | 2020 | 93 | 0.040 |
Why?
|
| Saponins | 1 | 2020 | 23 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2021 | 162 | 0.040 |
Why?
|
| Hospitals, Pediatric | 2 | 2016 | 795 | 0.040 |
Why?
|
| Neutrophils | 2 | 2017 | 362 | 0.040 |
Why?
|
| DNA, Complementary | 1 | 2021 | 470 | 0.040 |
Why?
|
| Public Health | 1 | 2023 | 286 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2020 | 51 | 0.040 |
Why?
|
| Tablets | 1 | 2020 | 36 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 563 | 0.040 |
Why?
|
| Forecasting | 1 | 2002 | 374 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 2001 | 177 | 0.040 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2020 | 59 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2024 | 710 | 0.040 |
Why?
|
| Decision Trees | 1 | 2020 | 51 | 0.040 |
Why?
|
| Disease Management | 2 | 2014 | 565 | 0.040 |
Why?
|
| Cold Temperature | 4 | 2004 | 86 | 0.040 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 2020 | 10 | 0.040 |
Why?
|
| Endemic Diseases | 1 | 2020 | 59 | 0.040 |
Why?
|
| Positive-Pressure Respiration | 1 | 2020 | 85 | 0.040 |
Why?
|
| Sphingolipids | 1 | 2020 | 35 | 0.040 |
Why?
|
| Carnitine | 1 | 2020 | 75 | 0.040 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 42 | 0.040 |
Why?
|
| Half-Life | 1 | 2020 | 162 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2020 | 159 | 0.040 |
Why?
|
| Cytidine Deaminase | 1 | 1999 | 32 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2021 | 780 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2002 | 314 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 45 | 0.040 |
Why?
|
| Program Development | 1 | 2000 | 190 | 0.040 |
Why?
|
| DNA Probes | 1 | 2019 | 124 | 0.040 |
Why?
|
| RNA Stability | 1 | 2020 | 87 | 0.040 |
Why?
|
| Belgium | 1 | 2019 | 44 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2019 | 77 | 0.040 |
Why?
|
| Alanine | 1 | 2020 | 184 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 153 | 0.040 |
Why?
|
| Patient Selection | 1 | 2003 | 736 | 0.040 |
Why?
|
| Hypercholesterolemia | 1 | 2001 | 236 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 1106 | 0.040 |
Why?
|
| Developed Countries | 1 | 2019 | 42 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 578 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2017 | 686 | 0.040 |
Why?
|
| Immunocompetence | 1 | 1998 | 33 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2002 | 504 | 0.040 |
Why?
|
| Alum Compounds | 2 | 1989 | 42 | 0.040 |
Why?
|
| Parturition | 1 | 2019 | 67 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 296 | 0.040 |
Why?
|
| Income | 1 | 2019 | 140 | 0.040 |
Why?
|
| Hypoxia | 1 | 2020 | 267 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 1999 | 216 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2000 | 457 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2005 | 638 | 0.040 |
Why?
|
| DNA, Ribosomal | 1 | 2018 | 57 | 0.040 |
Why?
|
| World Health Organization | 1 | 2018 | 119 | 0.040 |
Why?
|
| HIV | 1 | 2019 | 193 | 0.040 |
Why?
|
| Corynebacterium | 1 | 2017 | 12 | 0.040 |
Why?
|
| Granzymes | 1 | 2017 | 48 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2017 | 113 | 0.030 |
Why?
|
| Haemophilus influenzae | 1 | 2018 | 136 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 4 | 2008 | 155 | 0.030 |
Why?
|
| Immunodominant Epitopes | 1 | 2017 | 52 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 69 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 1160 | 0.030 |
Why?
|
| Drug Stability | 1 | 2016 | 62 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 197 | 0.030 |
Why?
|
| Genomics | 1 | 2025 | 1678 | 0.030 |
Why?
|
| Prevotella | 1 | 2016 | 10 | 0.030 |
Why?
|
| Reverse Genetics | 1 | 2016 | 16 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2016 | 74 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 288 | 0.030 |
Why?
|
| Child, Hospitalized | 1 | 2017 | 76 | 0.030 |
Why?
|
| Genetic Drift | 1 | 2016 | 23 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 94 | 0.030 |
Why?
|
| Cholesterol | 1 | 1999 | 574 | 0.030 |
Why?
|
| Prenatal Care | 1 | 2019 | 360 | 0.030 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2016 | 51 | 0.030 |
Why?
|
| Urinalysis | 1 | 1996 | 66 | 0.030 |
Why?
|
| Hematuria | 1 | 1996 | 55 | 0.030 |
Why?
|
| Temperature | 1 | 2016 | 326 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 1996 | 79 | 0.030 |
Why?
|
| Cell Fusion | 1 | 2015 | 38 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 2 | 1996 | 618 | 0.030 |
Why?
|
| Pichia | 1 | 2015 | 56 | 0.030 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2016 | 62 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 1999 | 1041 | 0.030 |
Why?
|
| Safety-Based Drug Withdrawals | 1 | 2015 | 1 | 0.030 |
Why?
|
| Nasal Decongestants | 1 | 2015 | 4 | 0.030 |
Why?
|
| Antitussive Agents | 1 | 2015 | 3 | 0.030 |
Why?
|
| Expectorants | 1 | 2015 | 8 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 253 | 0.030 |
Why?
|
| Streptococcus pneumoniae | 1 | 2018 | 380 | 0.030 |
Why?
|
| Mothers | 2 | 2015 | 372 | 0.030 |
Why?
|
| Intubation | 1 | 2015 | 15 | 0.030 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 918 | 0.030 |
Why?
|
| Bronchi | 1 | 2015 | 107 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 245 | 0.030 |
Why?
|
| Tachypnea | 1 | 2015 | 1 | 0.030 |
Why?
|
| High-Frequency Ventilation | 1 | 2015 | 17 | 0.030 |
Why?
|
| Heart Defects, Congenital | 1 | 2007 | 1887 | 0.030 |
Why?
|
| Cross Protection | 1 | 2014 | 7 | 0.030 |
Why?
|
| Leukocyte Reduction Procedures | 1 | 2014 | 3 | 0.030 |
Why?
|
| Multilevel Analysis | 1 | 2014 | 9 | 0.030 |
Why?
|
| Environment | 1 | 1996 | 154 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2015 | 144 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 1728 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2014 | 67 | 0.030 |
Why?
|
| Macrophages, Alveolar | 1 | 2014 | 47 | 0.030 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 1996 | 174 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 826 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 158 | 0.030 |
Why?
|
| Receptors, Fc | 1 | 2014 | 33 | 0.030 |
Why?
|
| Complement C1q | 1 | 2014 | 18 | 0.030 |
Why?
|
| Contig Mapping | 1 | 2014 | 56 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2015 | 318 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 153 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2004 | 3144 | 0.030 |
Why?
|
| Dogs | 1 | 2015 | 672 | 0.030 |
Why?
|
| Patient Transfer | 1 | 2015 | 110 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 608 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2014 | 240 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2020 | 2885 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2008 | 509 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2018 | 4922 | 0.020 |
Why?
|
| Catheterization, Peripheral | 1 | 2014 | 132 | 0.020 |
Why?
|
| Sputum | 1 | 2013 | 116 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2015 | 415 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 787 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2015 | 1147 | 0.020 |
Why?
|
| Radiography | 1 | 2014 | 824 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2017 | 750 | 0.020 |
Why?
|
| Virus Cultivation | 1 | 2011 | 77 | 0.020 |
Why?
|
| Serologic Tests | 1 | 2011 | 128 | 0.020 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2015 | 485 | 0.020 |
Why?
|
| Vitamin D | 1 | 2012 | 180 | 0.020 |
Why?
|
| Ribonucleosides | 1 | 1990 | 15 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 964 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1990 | 105 | 0.020 |
Why?
|
| Emergency Medicine | 1 | 2012 | 161 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 716 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 400 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 1990 | 251 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 910 | 0.020 |
Why?
|
| Protein Binding | 1 | 2014 | 1853 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 1068 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 1989 | 86 | 0.020 |
Why?
|
| Chemical Precipitation | 1 | 1989 | 15 | 0.020 |
Why?
|
| Herpesviridae Infections | 1 | 1990 | 146 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 1166 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 2653 | 0.020 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2008 | 29 | 0.020 |
Why?
|
| Hemagglutination Inhibition Tests | 2 | 2000 | 114 | 0.020 |
Why?
|
| Antigens | 1 | 1988 | 152 | 0.020 |
Why?
|
| Catheters, Indwelling | 1 | 1989 | 158 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 3 | 2002 | 4823 | 0.020 |
Why?
|
| Ovalbumin | 1 | 1988 | 321 | 0.020 |
Why?
|
| Pollen | 1 | 1988 | 48 | 0.020 |
Why?
|
| HT29 Cells | 1 | 2007 | 45 | 0.020 |
Why?
|
| Diarrhea, Infantile | 1 | 2007 | 36 | 0.020 |
Why?
|
| Immunoassay | 1 | 2007 | 137 | 0.020 |
Why?
|
| Pseudomonas Vaccines | 1 | 1986 | 1 | 0.020 |
Why?
|
| Mucus | 1 | 1986 | 38 | 0.020 |
Why?
|
| Quality of Life | 1 | 2016 | 2161 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2014 | 1618 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 1986 | 89 | 0.020 |
Why?
|
| Bacterial Vaccines | 1 | 1986 | 103 | 0.020 |
Why?
|
| Comorbidity | 2 | 2004 | 1626 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 1988 | 195 | 0.010 |
Why?
|
| Pulmonary Alveoli | 1 | 1986 | 142 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1990 | 1221 | 0.010 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 1989 | 313 | 0.010 |
Why?
|
| Phagocytosis | 1 | 1986 | 194 | 0.010 |
Why?
|
| HLA-A Antigens | 1 | 2004 | 34 | 0.010 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1986 | 180 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 2004 | 83 | 0.010 |
Why?
|
| Weight Loss | 1 | 2008 | 518 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 2004 | 299 | 0.010 |
Why?
|
| Drug Therapy, Combination | 2 | 1997 | 1165 | 0.010 |
Why?
|
| Immunologic Memory | 1 | 2003 | 200 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2003 | 966 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2002 | 148 | 0.010 |
Why?
|
| Platelet Count | 1 | 2002 | 143 | 0.010 |
Why?
|
| Macrophages | 1 | 1986 | 697 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2002 | 353 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2007 | 681 | 0.010 |
Why?
|
| Life Expectancy | 1 | 2001 | 60 | 0.010 |
Why?
|
| Korea | 1 | 2001 | 35 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2002 | 400 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2001 | 103 | 0.010 |
Why?
|
| Carcinoma, Small Cell | 1 | 2001 | 49 | 0.010 |
Why?
|
| Apolipoproteins E | 1 | 2001 | 203 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2002 | 216 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2003 | 449 | 0.010 |
Why?
|
| Milk, Human | 1 | 2003 | 311 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2002 | 569 | 0.010 |
Why?
|
| Virulence | 1 | 2001 | 278 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2002 | 237 | 0.010 |
Why?
|
| APOBEC-1 Deaminase | 1 | 1999 | 12 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2002 | 441 | 0.010 |
Why?
|
| Helper Viruses | 1 | 1999 | 46 | 0.010 |
Why?
|
| North America | 1 | 2000 | 266 | 0.010 |
Why?
|
| Alleles | 1 | 2004 | 1724 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2001 | 281 | 0.010 |
Why?
|
| Spleen | 1 | 1999 | 287 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 2000 | 513 | 0.010 |
Why?
|
| Rabbits | 1 | 1999 | 710 | 0.010 |
Why?
|
| Culture Media | 1 | 1998 | 183 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 766 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 1733 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 3169 | 0.010 |
Why?
|
| Anticholesteremic Agents | 1 | 1999 | 247 | 0.010 |
Why?
|
| Gambia | 1 | 1996 | 29 | 0.010 |
Why?
|
| Virology | 1 | 1996 | 36 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1996 | 192 | 0.010 |
Why?
|
| Steroids | 1 | 1997 | 211 | 0.010 |
Why?
|
| Air Microbiology | 1 | 1994 | 12 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 1996 | 285 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1997 | 314 | 0.010 |
Why?
|
| Neoplasms | 1 | 1989 | 3035 | 0.010 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 1996 | 255 | 0.010 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 1994 | 93 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2001 | 3979 | 0.010 |
Why?
|
| Leukemia | 1 | 1996 | 377 | 0.010 |
Why?
|
| Aging | 1 | 1999 | 1283 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1995 | 1593 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1990 | 360 | 0.000 |
Why?
|
| Aluminum | 1 | 1988 | 12 | 0.000 |
Why?
|
| Sulfates | 1 | 1988 | 36 | 0.000 |
Why?
|